Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
Wei Zhu, Miao Xu, Catherine Z. Chen, Hui Guo, Min Shen, Xin Hu, Paul Shinn, Carleen Klumpp‐Thomas, Sam Michael, Wei Zheng
Abstract
inhibitors that may have potential for further clinical evaluation as part of drug combination therapies to treating COVID-19 patients and as starting points for chemistry optimization for new drug development.
Topics & Concepts
Drug repositioningIC50ProteasePharmacologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusDrugVirologyDrug discoveryIndinavirViral replicationChemistryCoronavirus disease 2019 (COVID-19)MedicineEnzymeViral loadVirusIn vitroDiseaseBiochemistryInfectious disease (medical specialty)Internal medicineAntiretroviral therapySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesComputational Drug Discovery Methods